IL326828A - תרכובות פיפרידין-2,6-דיון אזטידיניל אוקסואיזואינדוליניל מוחלפות - Google Patents

תרכובות פיפרידין-2,6-דיון אזטידיניל אוקסואיזואינדוליניל מוחלפות

Info

Publication number
IL326828A
IL326828A IL326828A IL32682826A IL326828A IL 326828 A IL326828 A IL 326828A IL 326828 A IL326828 A IL 326828A IL 32682826 A IL32682826 A IL 32682826A IL 326828 A IL326828 A IL 326828A
Authority
IL
Israel
Prior art keywords
oxoisoindolinyl
piperidine
dione compounds
substituted azetidinyl
azetidinyl
Prior art date
Application number
IL326828A
Other languages
English (en)
Inventor
Pravin Sudhakar Shirude
Bharat Dinkar Shimpukade
Suresh Babu Vishwa Krishna Penmetsa
Original Assignee
Bristol Myers Squibb Co
Pravin Sudhakar Shirude
Bharat Dinkar Shimpukade
Suresh Babu Vishwa Krishna Penmetsa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Pravin Sudhakar Shirude, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa filed Critical Bristol Myers Squibb Co
Publication of IL326828A publication Critical patent/IL326828A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326828A 2023-09-02 2024-10-03 תרכובות פיפרידין-2,6-דיון אזטידיניל אוקסואיזואינדוליניל מוחלפות IL326828A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202311058934 2023-09-02
PCT/US2024/044649 WO2025064197A1 (en) 2023-09-02 2024-10-03 Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds

Publications (1)

Publication Number Publication Date
IL326828A true IL326828A (he) 2026-04-01

Family

ID=92843372

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326828A IL326828A (he) 2023-09-02 2024-10-03 תרכובות פיפרידין-2,6-דיון אזטידיניל אוקסואיזואינדוליניל מוחלפות

Country Status (3)

Country Link
AU (1) AU2024343845A1 (he)
IL (1) IL326828A (he)
WO (1) WO2025064197A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025226767A1 (en) * 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US20110176972A1 (en) 2008-05-29 2011-07-21 Saint-Gobain Centre De Recherches et D'Etudes Eur Cellular structure containing aluminium titanate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
JP5344375B2 (ja) 2009-09-30 2013-11-20 日本精機株式会社 回転角度検出装置
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
NO2694640T3 (he) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
BR112023020410A2 (pt) 2021-04-05 2023-11-28 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer

Also Published As

Publication number Publication date
AU2024343845A1 (en) 2026-04-16
WO2025064197A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
IL288236A (he) תרכובות של 3,2-דיהידרוקוינאזולין כמעכבים של nav1.8
IL326828A (he) תרכובות פיפרידין-2,6-דיון אזטידיניל אוקסואיזואינדוליניל מוחלפות
GB202200735D0 (en) Compounds
LT4587429T (lt) Pakeistieji oksoizoindolinilo piperidino 2,6-diono junginiai
IL325422A (he) תרכובת פיפרידין-2,6-דיון אוקסואיזואינדולינילית חליפית כגורם נוגד סרטן
GB202208643D0 (en) Compounds
CA3303134A1 (en) Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
CA3304009A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
AU2024342875A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
HK40128683A (zh) 取代的氧代异吲哚啉基哌啶-2，6-二酮化合物
GB202214796D0 (en) Compounds
GB202208151D0 (en) Compounds
GB202208160D0 (en) Compounds
GB202201996D0 (en) Compounds
CA3294322A1 (en) Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
CA3296396A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
GB202216044D0 (en) Kissthestarzdesigns, kissthestars, petrasdigicity
GB202214460D0 (en) Tchaman-aijuhoh12circlexdoKSgachachatchamanaijuhoh12circlexdotMaZelizelizeliganjuYohchakukeiMoShoshoshoshuhshuhshuhtennaizi-neobey80,000XOnlyShosshoshoshuhshu
GB202214459D0 (en) tchaman-aijuhoh12circledotksgachachatchamanaijuhoh12circlexdotmazelizelizeliganjuyohchakukeimoshoshoshoshuhshuhshutennaizo-neobey80,000xonlyshoshoshoshuhshuhs
GB202300995D0 (en) Compounds
GB202301000D0 (en) Compounds
GB202300922D0 (en) Compounds
GB202219706D0 (en) Compounds
GB202219534D0 (en) Compounds
GB202217844D0 (en) Compounds